Fruquintinib in the Cross-line Treatment of Refractory mCRC

Conditions

• Fruquintinib
• Metastatic Colorectal Cancer

Interventions

• DRUG: Fruquintinib+PD-1 inhibitors
• DRUG: Fruquintinib+TAS-102

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology